25.05.2010 • News

Henkel CEO Sees Russia No.4 Market in 4 Years

Henkel CEO Kasper Rorsted
Henkel CEO Kasper Rorsted

Henkel expects Russia to become its fourth-largest market over the next four years, a Russian business daily quoted its chief executive as saying in an interview published on Monday.

"We expect that already in the mid-term prospective markets like Russia will be showing faster growth than western Europe and the U.S.," Kasper Rorsted told Vedomosti newspaper.

Russia is currently Henkel's sixth or seventh-biggest market and the company plans to open a €10 million ($12.5 million) adhesives materials factory there in July and to build two more such plants by 2012, Rorsted was quoted as saying.

"I am sure that emerging markets will be out of the crisis sooner than developed (markets)," Rorsted said. Henkel, whose international rivals include Unilever, P&G and Colgate-Palmolive, earlier this month gave a cautious outlook for 2010, pointing to the Greek debt crisis and rising raw material costs.

Its Russian sales rose 12% in 2009 to €857.5 million against a 4% drop in total sales to around €14 billion.

Company

Henkel AG & Co. KGaA

Henkelstr. 67
40589 Düsseldorf
Germany

Company contact







Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.